Idebenone (Raxone®) for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)
The National Health Care Institute has carried out an assessment of the medicinal product idebenone (Raxone®).
Idebenone (Raxone®) is not interchangeable with any product in the GVS. Based on the above-mentioned considerations, The National Health Care Institute advised the Minister of WVS to include idebenone on List 1B and List 2 of the Health Insurance Decree. Inclusion on List 1B will involve additional costs.
Indication
Idebenone (Raxone®) is an orphan drug and is indicated for the treatment of vision impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy (LHON). LHON is a hereditary disorder characterised by sudden vision impairment in both eyes. Idebenone is available as 150 mg film-coated tablet. The recommended dose is 900 mg idebenone per day, with a dose of two 150-mg tablets three times a day.